北京奥赛康药业股份有限公司 2025年第三季度报告

Core Viewpoint - The company, Beijing Osai Kang Pharmaceutical Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2][7]. Financial Data - The third-quarter financial report has not been audited [3][8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for this quarter [3]. Board Meeting - The seventh board of directors held its fifth meeting on October 28, 2025, where all nine directors attended, and the meeting complied with relevant laws and regulations [7]. - The board unanimously approved the third-quarter report with a voting result of 9 in favor, 0 against, and 0 abstentions [7][8]. Shareholder Information - The report includes details on the total number of ordinary shareholders and the shareholding status of the top ten shareholders [4]. - There are no changes in the borrowing or returning of shares by major shareholders due to transfer and financing activities [5]. Other Important Matters - The company confirms that there are no other significant matters to disclose in this quarter's report [5].